<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429182</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0280</org_study_id>
    <nct_id>NCT00429182</nct_id>
  </id_info>
  <brief_title>Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn the relationship of high-dose&#xD;
      chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast&#xD;
      cancer. The study also will investigate the role of CTCs in breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may&#xD;
      slow or stop their growth and spread throughout the body. This may cause the cancer cells to&#xD;
      die. Carboplatin and thiotepa are designed to interfere with the growth of cancer cells by&#xD;
      stopping cell division, which may cause the cells to die. Mesna is designed to prevent&#xD;
      toxicities from cyclophosphamide. Granulocyte colony-stimulating factor (G-CSF or GCSF) is&#xD;
      designed to help your white blood count recover after transplant.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be given G-CSF twice a&#xD;
      day through a needle under the skin (subcutaneous injection), on Days 1-5. On Day 5, stem&#xD;
      cell collection will begin. You will have a catheter placed into a vein in your chest. A&#xD;
      central venous catheter is a sterile flexible tube that will be placed into a large vein&#xD;
      while you are under local anesthesia. Your physician will explain this procedure to you in&#xD;
      more detail, and you will be required to sign a separate consent form for this procedure.&#xD;
&#xD;
      If further shrinkage of tumor is needed, the doctor may use chemotherapy combined with G-CSF&#xD;
      described above. Your doctor will explain this procedure to you in more detail, and you will&#xD;
      be asked to sign a separate consent form for this procedure.&#xD;
&#xD;
      Blood will be removed from your body through the catheter and passed through a machine that&#xD;
      separates the stem cells from the other cells. The stem cells will be frozen for storage, and&#xD;
      the blood will be returned to your body. This 3-hour process is called apheresis. The process&#xD;
      will be done once a day for 1-6 days until enough stem cells are collected. Blood ( about 4&#xD;
      teaspoons) will be collected at the first Apheresis to have as a comparison sample to check&#xD;
      for any breast cancer leftover in the blood.&#xD;
&#xD;
      The collected blood cells will go through a filter to select out the blood stem cells and the&#xD;
      CTCs will be left behind.&#xD;
&#xD;
      Blood (about 2 tablespoons) will be drawn daily during peripheral blood stem cell collection.&#xD;
&#xD;
      On Days 6, 5, 4, and 3 before the transplant, you will receive cyclophosphamide, mesna,&#xD;
      thiotepa, and carboplatin through a needle in your vein. Blood (about 2 teaspoons) will be&#xD;
      drawn for routine tests.&#xD;
&#xD;
      On Day 0, your stem cells will be transplanted. Stem cells will go through a device to remove&#xD;
      the breast cancer cells. If the bone marrow is collected because there was not enough stem&#xD;
      cells, researchers will not treat the bone marrow to remove breast cancer cells. Collected&#xD;
      breast cancer cells will be studied to understand the biological role of these cancer cells.&#xD;
&#xD;
      After the transplant, G-CSF will be given through a needle under your skin until the white&#xD;
      blood cell count is normal for 3 days in a row.&#xD;
&#xD;
      Blood (about 2 tablespoons) will be drawn daily after the transplant while you are still in&#xD;
      the hospital. You are expected to remain in the hospital for 3 weeks. Once you are released&#xD;
      from the hospital, you will have blood (about 2 tablespoons) drawn for routine tests every&#xD;
      week until your cell counts recover.&#xD;
&#xD;
      Five (5) weeks after your transplant, if your doctor thinks it is needed, you will have&#xD;
      radiation therapy, hormonal therapy, or receive trastuzumab.&#xD;
&#xD;
      At Months 1, 3, 6, 9, 12, 16, 20, and 24 after the transplant, your complete medical history&#xD;
      will be recorded, and you will have a physical exam. You will have a chest X-ray and bone&#xD;
      scan. If your doctor thinks it is needed, you will have an x-ray of hot spots which are areas&#xD;
      that show positive on the bone scan. If your doctor thinks it is needed, you may have a CT&#xD;
      scan of the head, a mammogram, or a breast ultrasound performed. At Months 1 and 3 after the&#xD;
      transplant, you will have a PET/CT scan. At Months 6, 9, 12, 16, 20, and 24 after the&#xD;
      transplant, you will have a CT scan of the chest and abdomen then as needed to check the&#xD;
      status of the disease. Blood (about 2 teaspoons) will be drawn to measure cancer markers and&#xD;
      CTCs.&#xD;
&#xD;
      While on study you must notify the doctor of any new drugs you are taking.&#xD;
&#xD;
      This is an investigational study. The transplant is not FDA approved. The drugs G-CSF,&#xD;
      cyclophosphamide, carboplatin, and thiotepa are all approved by the FDA and commercially&#xD;
      available. The CliniMACS device is not commercially available or FDA approved. The CliniMACS&#xD;
      device is being used in research only and will be provided free of charge. Up to 70 patients&#xD;
      will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</measure>
    <time_frame>Baseline to 1 month post AHST</time_frame>
    <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>Overall study (baseline to disease progression)</time_frame>
    <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin + Cyclophosphamide + Thiotepa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem Cell Transplant on Day 0.</description>
    <arm_group_label>High-dose chemotherapy</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Autologous hematopoietic stem cell transplantation</other_name>
    <other_name>AHST</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 55 years old&#xD;
&#xD;
          2. Metastatic breast carcinoma.&#xD;
&#xD;
          3. Histological confirmation of invasive breast carcinoma&#xD;
&#xD;
          4. Complete or partial response to pre-transplant standard-dose chemotherapy, or hormonal&#xD;
             therapy. For bone disease, stable disease (SD) is allowed.&#xD;
&#xD;
          5. Patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor&#xD;
             (PR).&#xD;
&#xD;
          6. Persistent detectable or non-detectable CTCs by Veridex Technology after completion of&#xD;
             standard therapy.&#xD;
&#xD;
          7. Zubrod performance status 0 or 1.&#xD;
&#xD;
          8. Patients must have adequate hematological parameters (White Blood Count/WBC &gt;=&#xD;
             3,000/mm3; platelet count &gt;= 100,000/mm3)&#xD;
&#xD;
          9. Adequate renal function (serum creatinine &lt;= 1.5mg/dl)&#xD;
&#xD;
         10. Adequate liver function (total bilirubin, serum glutamate pyruvate transaminase (SGPT)&#xD;
             &lt;= 2 times normal).&#xD;
&#xD;
         11. Adequate cardiac function (Left ventricular ejection fraction (LVEF)&gt;= 50%).&#xD;
&#xD;
         12. Adequate pulmonary function (Carbon Monoxide Diffusing Capacity (DLCO)&gt;= 50% of&#xD;
             predicted value).&#xD;
&#xD;
         13. Females of childbearing (women who are post-menopausal &lt; 1 year, not surgically&#xD;
             sterilized, or not abstinent) potential must use adequate contraception.&#xD;
&#xD;
         14. Patients must sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior HDCT with Autologous hematopoietic stem cell transplantation (AHST) in adjuvant&#xD;
             setting.&#xD;
&#xD;
          2. History or presence of brain/leptomeningeal metastasis.&#xD;
&#xD;
          3. History of other malignancies except cured non-melanoma skin cancer or cured cervical&#xD;
             carcinoma in situ.&#xD;
&#xD;
          4. Presence of other severe medical illnesses or conditions. Severe heart disease,&#xD;
             (myocardial ischemia, myocardial infarction, etc.) Pulmonary disease (COPD,&#xD;
             asthma,etc). Renal failure and hepatic failure.&#xD;
&#xD;
          5. Clinically significant active infections (patient requiring IV antibiotics,&#xD;
             uncontrolled infections, or hospitalized due to infections).&#xD;
&#xD;
          6. HIV infection.&#xD;
&#xD;
          7. Pregnant or lactating women.&#xD;
&#xD;
          8. Medical, social or psychologic factors which would prevent the patient from receiving&#xD;
             or cooperating with the full course of therapy or understanding the informed consent&#xD;
             procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>February 28, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2013</results_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>breast carcinoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Neosar</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>Purged Autologous Stem Cells</keyword>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>CTCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 27, 2007 to July 25, 2011. All Recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa&#xD;
Carboplatin : Target area under the curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Stem Cell Transplant : Stem Cell Transplant on Day 0.&#xD;
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not evaluable, Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa&#xD;
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Stem Cell Transplant : Stem Cell Transplant on Day 0.&#xD;
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</title>
        <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
        <time_frame>Baseline to 1 month post AHST</time_frame>
        <population>Twenty-one participants provided blood samples for the enumeration of CTCs, before apheresis (baseline) and at one month after AHST.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy</title>
            <description>Carboplatin + Cyclophosphamide + Thiotepa&#xD;
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Stem Cell Transplant : Stem Cell Transplant on Day 0.&#xD;
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products</title>
          <description>Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.</description>
          <population>Twenty-one participants provided blood samples for the enumeration of CTCs, before apheresis (baseline) and at one month after AHST.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival (PFS)</title>
        <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
        <time_frame>Overall study (baseline to disease progression)</time_frame>
        <population>Six participants were not evaluable for outcome assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy</title>
            <description>Carboplatin + Cyclophosphamide + Thiotepa&#xD;
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Stem Cell Transplant : Stem Cell Transplant on Day 0.&#xD;
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival (PFS)</title>
          <description>Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.</description>
          <population>Six participants were not evaluable for outcome assessment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-dose Chemotherapy</title>
          <description>Carboplatin + Cyclophosphamide + Thiotepa&#xD;
Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.&#xD;
Stem Cell Transplant : Stem Cell Transplant on Day 0.&#xD;
Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoto Ueno, MD / Professor</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

